Table 2 Frequency and percentages across the 168 included articles for reported subtypes of LS and evaluated treatments
From: Endpoints and outcomes for localized scleroderma/morphea: a scoping literature review
N (%)1 | |
|---|---|
Types/Subtypes | |
Craniofacial scleroderma | 100 (59.5) |
Generalized morphea | 95 (56.5) |
Linear morphea, unspecified | 60 (35.7) |
Circumbscribed morphea, unspecified | 51 (30.4) |
Mixed subtype | 42 (25.0) |
Linear morphea, trunk/limb | 35 (20.8) |
Circumscribed morphea, deep | 23 (13.7) |
Pansclerotic morphea | 22 (13.1) |
Eosinophilic Fasciitis | 13 (7.7) |
Circumbscribed morphea, superficial | 8 (4.8) |
Unspecified | 16 (9.5) |
Treatments | |
Corticosteroids (oral and parenteral) | 76 (45.2) |
Methotrexate | 72 (42.9) |
Phototherapy / UV therapy | 50 (29.8) |
Topical creams / medications | 37 (22.0) |
Plastic / reconstructive surgery | 35 (20.8) |
Mycophenolate Mofetil (MMF) | 20 (11.9) |
Antibiotic | 4 (2.4) |
Traditional Chinese medicine | 2 (1.2) |
Acupuncture | 1 (0.6) |
Other | 66 (39.3) |